BG61202B2 - Стабилизиран фармацевтичен състав и неговото получаване - Google Patents

Стабилизиран фармацевтичен състав и неговото получаване Download PDF

Info

Publication number
BG61202B2
BG61202B2 BG098473A BG9847394A BG61202B2 BG 61202 B2 BG61202 B2 BG 61202B2 BG 098473 A BG098473 A BG 098473A BG 9847394 A BG9847394 A BG 9847394A BG 61202 B2 BG61202 B2 BG 61202B2
Authority
BG
Bulgaria
Prior art keywords
pharmaceutical composition
compound
hydrogen
composition according
alkyl
Prior art date
Application number
BG098473A
Other languages
Bulgarian (bg)
English (en)
Inventor
Tadashi Makino
Tetsuro Tabata
Shin-Ichiro Hirai
Original Assignee
Takeda Chemical Industries, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26367776&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BG61202(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Chemical Industries, Ltd. filed Critical Takeda Chemical Industries, Ltd.
Publication of BG61202B2 publication Critical patent/BG61202B2/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BG098473A 1986-02-13 1994-02-14 Стабилизиран фармацевтичен състав и неговото получаване BG61202B2 (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2956786 1986-02-13
JP3805986 1986-02-21

Publications (1)

Publication Number Publication Date
BG61202B2 true BG61202B2 (bg) 1997-02-28

Family

ID=26367776

Family Applications (1)

Application Number Title Priority Date Filing Date
BG098473A BG61202B2 (bg) 1986-02-13 1994-02-14 Стабилизиран фармацевтичен състав и неговото получаване

Country Status (7)

Country Link
US (2) US5045321A (fr)
EP (3) EP0237200B1 (fr)
BG (1) BG61202B2 (fr)
CA (1) CA1327010C (fr)
DE (3) DE3751845T2 (fr)
HK (2) HK188195A (fr)
SG (1) SG50619A1 (fr)

Families Citing this family (171)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6749864B2 (en) 1986-02-13 2004-06-15 Takeda Chemical Industries, Ltd. Stabilized pharmaceutical composition
US5433959A (en) * 1986-02-13 1995-07-18 Takeda Chemical Industries, Ltd. Stabilized pharmaceutical composition
GB2189699A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
US5026560A (en) * 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
JPH03504497A (ja) * 1988-05-25 1991-10-03 ビイク　グルデン　ロンベルク　ヒエーミツシエ　フアブリーク　ゲゼルシヤフト　ミツト　ベシユレンクテル　ハフツング 新規フルオルアルコキシ化合物
DK399389A (da) * 1988-08-18 1990-02-19 Takeda Chemical Industries Ltd Injicerbare oploesninger
GR1002098B (en) * 1989-06-08 1995-12-28 Squibb & Sons Inc Pharmaceutical composition having good stability
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
ZA919510B (en) * 1990-12-05 1992-10-28 Smithkline Beecham Corp Pharmaceutical compositions
IT1250701B (it) * 1991-07-24 1995-04-21 Angelini Francesco Ist Ricerca Composizione farmaceutica solida per uso orale a base di dapiprazolo
HU9203780D0 (en) * 1991-12-12 1993-03-29 Sandoz Ag Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them
CA2138787A1 (fr) * 1992-07-08 1994-01-20 Clifton Augustus Baile Soulagement des ulceres d'estomac chez les porcins
WO1994002140A1 (fr) * 1992-07-17 1994-02-03 Astra Aktiebolag Composition pharmaceutique contenant un agent antiulcereux
JPH0656665A (ja) * 1992-08-03 1994-03-01 Nippon Chemiphar Co Ltd イミダゾール誘導体を含有する胃溶性抗潰瘍剤
ZA937382B (en) * 1992-10-06 1994-04-29 Warner Lambert Co Novel composition for peroral therapy of cognitionimpairment and a process therefor
ES2133158T3 (es) * 1993-01-19 1999-09-01 Warner Lambert Co Formulacion ci-981 oral, estable y proceso de preparacion del mismo.
US6875872B1 (en) * 1993-05-28 2005-04-05 Astrazeneca Compounds
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
EP0995447A1 (fr) * 1993-09-09 2000-04-26 Takeda Chemical Industries, Ltd. Formulation comprenant un agent antibactérien et un agent antiulcère
DE69430921T2 (de) * 1993-10-12 2003-02-13 Mitsubishi Pharma Corp., Osaka Darmlösliche grannulatkörner enthaltende tablette
TW280770B (fr) 1993-10-15 1996-07-11 Takeda Pharm Industry Co Ltd
US5399356A (en) * 1994-03-24 1995-03-21 The Procter & Gamble Company Process for making solid dose forms containing bismuth
ES2094694B1 (es) * 1995-02-01 1997-12-16 Esteve Quimica Sa Nueva formulacion farmaceuticamente estable de un compuesto de bencimidazol y su proceso de obtencion.
SE9500478D0 (sv) * 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process
CH687810A5 (de) * 1995-05-24 1997-02-28 Mepha Ag Pelletformulierung mit Omeprazol.
US5824339A (en) * 1995-09-08 1998-10-20 Takeda Chemical Industries, Ltd Effervescent composition and its production
DK0814782T3 (da) * 1995-12-22 2002-12-16 Nissan Chemical Ind Ltd Farmaceutisk præparat stabiliseret med et basisk middel
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6645988B2 (en) * 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6699885B2 (en) * 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US6090419A (en) * 1996-05-02 2000-07-18 Mccormick & Company, Inc. Salt compositions and method of preparation
US8071128B2 (en) * 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
US6623759B2 (en) 1996-06-28 2003-09-23 Astrazeneca Ab Stable drug form for oral administration with benzimidazole derivatives as active ingredient and process for the preparation thereof
CA2204580A1 (fr) * 1997-05-06 1998-11-06 Michel Zoghbi Synthese de derives de la pyridine utiles en pharmacie
US6437139B1 (en) 1997-05-06 2002-08-20 Pdi-Research Laboratories, Inc. Synthesis of pharmaceutically useful pyridine derivatives
SI9700186B (sl) 1997-07-14 2006-10-31 Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. Nova farmacevtska oblika z nadzorovanim sproscanjem zdravilnih ucinkovin
ES2137862B1 (es) * 1997-07-31 2000-09-16 Intexim S A Preparacion farmaceutica oral que comprende un compuesto de actividad antiulcerosa y procedimiento para su obtencion.
US6174548B1 (en) 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6096340A (en) * 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
DK173431B1 (da) 1998-03-20 2000-10-23 Gea Farmaceutisk Fabrik As Farmaceutisk formulering omfattende en 2-[[(2-pyridinyl)methyl]sulfinyl]benzimidazol med anti-ulcusaktivitet samt fremgangs
ES2373864T3 (es) * 1998-04-20 2012-02-09 Eisai R&D Management Co., Ltd. Composición estabilizada que contiene un compuesto de tipo bencimidazol.
PT1121103E (pt) 1998-05-18 2007-02-28 Takeda Pharmaceutical Comprimidos de desintegração oral compreendendo um benzimidazole
ES2237121T3 (es) 1998-07-28 2005-07-16 Takeda Pharmaceutical Company Limited Preparacion solida disgregable rapidamente.
US6733778B1 (en) * 1999-08-27 2004-05-11 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US20040224989A1 (en) * 1999-01-29 2004-11-11 Barberich Timothy J. S-lansoprazole compositions and methods
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
IL130602A0 (en) * 1999-06-22 2000-06-01 Dexcel Ltd Stable benzimidazole formulation
SE9902386D0 (sv) * 1999-06-22 1999-06-22 Astra Ab New formulation
US20030236236A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US6262085B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6312712B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Method of improving bioavailability
US6262086B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Pharmaceutical unit dosage form
US6780880B1 (en) 1999-08-26 2004-08-24 Robert R. Whittle FT-Raman spectroscopic measurement
US6326384B1 (en) 1999-08-26 2001-12-04 Robert R. Whittle Dry blend pharmaceutical unit dosage form
US6369087B1 (en) * 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6316020B1 (en) 1999-08-26 2001-11-13 Robert R. Whittle Pharmaceutical formulations
US6312723B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Pharmaceutical unit dosage form
US6268385B1 (en) 1999-08-26 2001-07-31 Robert R. Whittle Dry blend pharmaceutical formulations
KR100359256B1 (ko) * 1999-10-06 2002-11-04 한미약품공업 주식회사 란소프라졸의 개선된 제조방법
AU782538B2 (en) 1999-10-20 2005-08-04 Eisai Co. Ltd. Method for stabilizing benzimidazole compounds
AU1545301A (en) * 1999-11-22 2001-06-04 Philippe R. Baudier Stable acid labile benzimidazole pharmaceutical compositions
US20060034937A1 (en) * 1999-11-23 2006-02-16 Mahesh Patel Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
DE19959419A1 (de) 1999-12-09 2001-06-21 Ratiopharm Gmbh Stabile galenische Zubereitungen umfassend ein Benzimidazol und Verfahren zu ihrer Herstellung
US7732404B2 (en) 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
US6242003B1 (en) 2000-04-13 2001-06-05 Novartis Ag Organic compounds
US6544556B1 (en) * 2000-09-11 2003-04-08 Andrx Corporation Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor
WO2002026210A2 (fr) * 2000-09-29 2002-04-04 Geneva Pharmaceuticals Inc. Formulation d'inhibiteur de la pompe à protons
KR100430575B1 (ko) * 2001-02-21 2004-05-10 주식회사 씨트리 란소프라졸 및 그 중간체의 제조방법
US20060127474A1 (en) * 2001-04-11 2006-06-15 Oskar Kalb Pharmaceutical compositions comprising fluvastatin
US6800264B1 (en) 2001-04-27 2004-10-05 United States Aluminate Company Process for stabilizing aqueous aluminate and zirconate solutions
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
MXPA04002973A (es) 2001-09-28 2005-06-20 Johnson & Johnson Formas de dosis de liberacion modificada.
US9358214B2 (en) 2001-10-04 2016-06-07 Adare Pharmaceuticals, Inc. Timed, sustained release systems for propranolol
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
ES2426723T3 (es) * 2001-10-17 2013-10-24 Takeda Pharmaceutical Company Limited Gránulos que contienen gran cantidad de compuesto químico inestable en medio ácido
WO2003063840A2 (fr) * 2002-01-25 2003-08-07 Santarus, Inc. Administration par voie muqueuse d'inhibiteurs de la pompe a protons
KR100464174B1 (ko) * 2002-03-06 2005-01-03 코오롱유화주식회사 설피닐 벤즈이미다졸 유도체의 제조방법
JP4732696B2 (ja) 2002-04-09 2011-07-27 フラメル・テクノロジー 活性成分の改変された放出のための、マイクロカプセルの水性懸濁液形態での経口医薬品製剤
ES2314227T7 (es) * 2002-04-09 2012-11-19 Flamel Technologies Formulacion farmaceutica oral en forma de suspension acuosa de microcapsulas que permiten la liberacion modificada de amoxilicina.
US20030228363A1 (en) * 2002-06-07 2003-12-11 Patel Mahendra R. Stabilized pharmaceutical compositons containing benzimidazole compounds
KR100873419B1 (ko) * 2002-06-18 2008-12-11 페어차일드코리아반도체 주식회사 높은 항복 전압, 낮은 온 저항 및 작은 스위칭 손실을갖는 전력용 반도체 소자
US20040028737A1 (en) * 2002-08-12 2004-02-12 Kopran Research Laboratories Limited Enteric coated stable oral pharmaceutical composition of acid unstable drug and process for preparing the same
EP1501824B1 (fr) * 2002-08-21 2007-10-10 Teva Pharmaceutical Industries Ltd Procede de purification de lansoprazole
MY148805A (en) * 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
US8697094B2 (en) 2002-10-16 2014-04-15 Takeda Pharmaceutical Company Limited Stable solid preparations
AU2002367936A1 (en) * 2002-10-24 2004-05-25 United States Aluminate Company Process for stabilizing aqueous aluminate and zirconate solutions
US8367111B2 (en) 2002-12-31 2013-02-05 Aptalis Pharmatech, Inc. Extended release dosage forms of propranolol hydrochloride
WO2004066924A2 (fr) * 2003-01-24 2004-08-12 Andrx Labs Llc Nouvelle formulation pharmaceutique contenant un inhibiteur de pompe a proton et un antiacide
CA2515130A1 (fr) * 2003-02-05 2004-08-26 Teva Pharmaceutical Industries Ltd. Procede de stabilisation de lansoprazole
TWI367759B (en) * 2003-02-20 2012-07-11 Santarus Inc A novel formulation, omeprazole antacid complex-immediate release, for rapid and sustained suppression of gastric acid
US20050220870A1 (en) * 2003-02-20 2005-10-06 Bonnie Hepburn Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
WO2004093875A1 (fr) * 2003-04-22 2004-11-04 Dr. Reddy's Laboratories Limited Formulations pharmaceutiques orales à base de principes actifs labiles en milieu acide et de dérivés glucides hydrosolubles, utilisation de ces formulations, et procédé de fabrication approprié
ES2234393B2 (es) * 2003-04-29 2006-09-01 Laboratorios Belmac, S.A. "formulaciones de pelets de compuestos bencimidazolicos antiulcerosos y labiles al acido".
AU2004257864A1 (en) * 2003-07-18 2005-01-27 Santarus, Inc. Pharmaceutical formulation and method for treating acid-caused gastrointestinal disorders
CA2531564C (fr) * 2003-07-18 2016-01-19 Santarus, Inc. Formulations pharmaceutiques utilisees pour inhiber une secretion acide et procede de fabrication associe
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US20050232992A1 (en) * 2003-09-03 2005-10-20 Agi Therapeutics Limited Proton pump inhibitor formulations, and methods of preparing and using such formulations
US20060003002A1 (en) * 2003-11-03 2006-01-05 Lipocine, Inc. Pharmaceutical compositions with synchronized solubilizer release
US20070292498A1 (en) * 2003-11-05 2007-12-20 Warren Hall Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers
EP1718303A4 (fr) * 2004-02-10 2010-09-01 Santarus Inc Combinaison d'un inhibiteur de la pompe a protons, d'un tampon et d'un medicament anti-inflammatoire non steroidien
US20050214371A1 (en) * 2004-03-03 2005-09-29 Simona Di Capua Stable pharmaceutical composition comprising an acid labile drug
CA2557634A1 (fr) * 2004-03-04 2005-09-15 Takeda Pharmaceutical Company Limited Preparation de capsule stable
CA2561700A1 (fr) * 2004-04-16 2005-12-15 Santarus, Inc. Combinaison d'un inhibiteur de la pompe a protons, d'un agent tampon et d'un agent prokinetique
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8461187B2 (en) 2004-06-16 2013-06-11 Takeda Pharmaceuticals U.S.A., Inc. Multiple PPI dosage form
US20050281876A1 (en) 2004-06-18 2005-12-22 Shun-Por Li Solid dosage form for acid-labile active ingredient
US20060024362A1 (en) * 2004-07-29 2006-02-02 Pawan Seth Composition comprising a benzimidazole and process for its manufacture
US8747895B2 (en) 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
WO2006047493A2 (fr) 2004-10-21 2006-05-04 Eurand Pharmaceuticals Limited Compositions pharmaceutiques a saveur masquee avec substances porogenes gastrosolubles
US20060105038A1 (en) * 2004-11-12 2006-05-18 Eurand Pharmaceuticals Limited Taste-masked pharmaceutical compositions prepared by coacervation
EP1833469A2 (fr) * 2005-01-03 2007-09-19 Lupin Ltd. Composition pharmaceutique de substances labiles acides
FR2881957B1 (fr) * 2005-02-16 2008-08-08 Solvay Comprimes comprenant une substance biologiquement active et un excipient
US20060210637A1 (en) * 2005-03-17 2006-09-21 Qpharma, Llc Stable tablet dosage forms of proton pump inhibitors
US9040564B2 (en) * 2005-04-28 2015-05-26 Eisai R&D Management Co., Ltd. Stabilized composition
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
US20060252830A1 (en) * 2005-05-06 2006-11-09 Brandon Stephen F Method for the treatment of magnesium and potassium deficiencies
US20060252831A1 (en) * 2005-05-06 2006-11-09 Christopher Offen Method for the treatment of magnesium and potassium deficiencies
FR2885526B1 (fr) * 2005-05-13 2007-07-27 Flamel Technologies Sa Medicament oral a base d'inhibiteur de pompe a protons
US20070026071A1 (en) * 2005-07-28 2007-02-01 Qpharma, Llc Magnesium salt proton pump inhibitor dosage forms
CN101309917B (zh) * 2005-10-06 2013-09-11 奥斯拜客斯制药有限公司 具有增强治疗性质的胃h+，k+-atp酶氘代抑制剂
WO2007041790A1 (fr) * 2005-10-14 2007-04-19 Jon Pty Limited Sels d'inhibiteurs de la pompe à protons et procédé servant à préparer ceux-ci
EP1785135A1 (fr) 2005-11-10 2007-05-16 Laboratorios Del Dr. Esteve, S.A. Nouvelles compositions galéniques stabilisées comprenant du lanzoprazole et leur préparation
US20100297226A1 (en) * 2006-06-01 2010-11-25 Dexcel Pharma Technologies Ltd. Multiple unit pharmaceutical formulation
WO2007143507A2 (fr) * 2006-06-05 2007-12-13 Auspex Pharmaceuticals, Inc. Préparation et utilité d'analogues d'érythromycine substitués
US20090092658A1 (en) * 2007-10-05 2009-04-09 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
CA2665226C (fr) 2006-10-05 2014-05-13 Santarus, Inc. Nouvelles formulations pour une liberation immediate d'inhibiteurs de pompe a protons et procedes d'utilisation de ces formulations
US20080103169A1 (en) 2006-10-27 2008-05-01 The Curators Of The University Of Missouri Compositions comprising acid labile proton pump inhibiting agents, at least one other pharmaceutically active agent and methods of using same
WO2008080092A2 (fr) 2006-12-22 2008-07-03 Ironwood Pharmaceuticals, Inc. Méthodes et compositions pour le traitement de troubles oesophagiens
US20080194307A1 (en) * 2007-02-13 2008-08-14 Jeff Sanger Sports-based game of chance
RU2010119041A (ru) * 2007-10-12 2011-11-20 Такеда Фармасьютикалз Норт Америка, Инк. (Us) Способы лечения нарушений желудочно-кишечного тракта, независимого от потребления пищи
KR20100097145A (ko) * 2007-11-27 2010-09-02 오하라 야꾸힝 고교 가부시키가이샤 조립물의 제조 방법
JP2011512416A (ja) 2008-02-20 2011-04-21 ザ・キュレイターズ・オブ・ザ・ユニバーシティー・オブ・ミズーリ オメプラゾール及びランソプラゾールの組合せと緩衝剤を含んでなる組成物とそれを使用する方法
EP2254556A2 (fr) 2008-03-11 2010-12-01 Takeda Pharmaceutical Company Limited Préparation solide orodispersible
US8861813B2 (en) * 2008-03-13 2014-10-14 Mallinckrodt Llc Multi-function, foot-activated controller for imaging system
US20090263475A1 (en) * 2008-04-21 2009-10-22 Nagaraju Manne Dexlansoprazole compositions
WO2009136398A2 (fr) 2008-05-06 2009-11-12 Dexcel Ltd Formule stable de benzimidazole
SI22806A (sl) * 2008-06-23 2009-12-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Nove kristalinične oblike natrijevega rabeprazola
KR20110079641A (ko) 2008-09-09 2011-07-07 아스트라제네카 아베 제약 조성물을 이를 필요로 하는 환자에게 전달하는 방법
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
MX2011013467A (es) 2009-06-25 2012-02-13 Astrazeneca Ab Metodo para tratar un paciente que corre el riesgo de desarollar una ulcera asociada a antiinflamatorio no esteroide (aine).
NZ597534A (en) * 2009-06-25 2013-09-27 Pozen Inc Method for treating a patient in need of aspirin therapy
EP2501383A4 (fr) * 2009-11-20 2013-06-26 Handa Pharmaceuticals Llc Formulation orale pour le dexlansoprazole
SG10201407965XA (en) 2009-12-02 2015-02-27 Aptalis Pharma Ltd Fexofenadine microcapsules and compositions containing them
AR079862A1 (es) * 2010-01-08 2012-02-22 Eurand Inc Composicion de topiramato con sabor enmascarado, un comprimido desintegrable oralmente que comprende la misma y metodo de preparacion
US20110189271A1 (en) * 2010-02-02 2011-08-04 Vishal Lad Pharmaceutical formulations of acid-labile drugs
US20130216617A1 (en) 2010-06-29 2013-08-22 Cadila Healthcare Limited Pharmaceutical compositions of (r)-lansoprazole
WO2012027331A1 (fr) 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions et procédés pour traiter ou prévenir un syndrome métabolique et des maladies et troubles associés
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
WO2012141160A1 (fr) * 2011-04-12 2012-10-18 沢井製薬株式会社 Préparation contenant de la pitavastatine et son procédé de production
US9539214B2 (en) 2011-12-28 2017-01-10 Pozen Inc. Compositions and methods for delivery of omeprazole plus acetylsalicylic acid
EA201591338A1 (ru) 2013-01-15 2016-01-29 Айронвуд Фармасьютикалз, Инк. Гастроретентивная лекарственная форма секвестранта желчных кислот с замедленным высвобождением для перорального применения
WO2016033549A2 (fr) 2014-08-28 2016-03-03 Lipocine Inc. Compositions de (17-ss)-3-oxoandrost-4-èn-17-yl tridécanoate et leurs procédés de préparation et d'utilisation
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
US20180015118A1 (en) 2015-02-03 2018-01-18 Ironwood Pharmaceuticals, Inc. Methods of treating upper gastrointestinal disorders in ppi refractory gerd
US20170042806A1 (en) 2015-04-29 2017-02-16 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
CN104817492B (zh) * 2015-05-22 2018-05-18 抚州三和医药化工有限公司 兰索拉唑中间体2-羟甲基-3-甲基-4-(2,2,2-三氟乙氧基）吡啶的分离纯化方法
WO2016205423A2 (fr) 2015-06-15 2016-12-22 Lipocine Inc. Composition et méthode pour l'administration orale de promédicaments androgènes
WO2017145146A1 (fr) 2016-02-25 2017-08-31 Dexcel Pharma Technologies Ltd. Compositions comprenant des inhibiteurs de la pompe à protons
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
CA3078723A1 (fr) 2016-11-28 2018-05-31 Nachiappan Chidambaram Traitement oral a base d'undecanoate de testosterone
EP3824296B1 (fr) 2018-07-20 2026-04-01 Lipocine Inc. Composition pharmaceutique orale comprenant du tridécanoate de testostérone et/ou du dodécanoate de testostérone pour le traitement des maladies du foie
JP2025532389A (ja) 2022-10-04 2025-09-29 ザビリュク，アルセニー 大動脈弁の石灰化の抑制
EP4681704A1 (fr) 2024-07-18 2026-01-21 BIOPROJET Pharma Nouvelles formulations de pitolisant

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1422176A (en) * 1973-05-05 1976-01-21 Beecham Group Ltd Pharmaceutical tablets
US4137325A (en) * 1977-03-17 1979-01-30 American Home Products Corporation Antisecretory oxamic acid esters
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
US4359465A (en) * 1980-07-28 1982-11-16 The Upjohn Company Methods for treating gastrointestinal inflammation
US4472409A (en) * 1981-11-05 1984-09-18 Byk Gulden Lomberg Chemische Fabrik Gesellschaft Mit Beschrankter Haftung 2-Pyridylmethyl thio(sulfinyl)benzimidazoles with gastric acid secretion inhibiting effects
SE8300736D0 (sv) * 1983-02-11 1983-02-11 Haessle Ab Novel pharmacologically active compounds
SE8301182D0 (sv) * 1983-03-04 1983-03-04 Haessle Ab Novel compounds
GB8307865D0 (en) * 1983-03-22 1983-04-27 Fujisawa Pharmaceutical Co Benzimidazole derivatives
JPS6019715A (ja) * 1983-07-12 1985-01-31 Nisshin Flour Milling Co Ltd 安定なイソカルボスチリル製剤
GB8417194D0 (en) * 1984-07-05 1984-08-08 Boots Co Plc Therapeutic agents
DE3427787A1 (de) * 1984-07-27 1986-01-30 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Wirkstoffkomplexe von 5-methoxy-2((4-methoxy-3,5-dimethyl-2-pyridyl) methylsulfinyl)-1h-benzimidazol mit cyclodextrinen, deren herstellung und arzneimittel
JPS6150978A (ja) * 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
JPS6150979A (ja) * 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
IL76839A (en) * 1984-10-31 1988-08-31 Byk Gulden Lomberg Chem Fab Picoline derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same
US4824856A (en) * 1985-08-14 1989-04-25 Nippon Chemiphar Co., Ltd. Method of protecting gastrointestinal tract
GB2189699A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments

Also Published As

Publication number Publication date
US5045321A (en) 1991-09-03
EP0237200A2 (fr) 1987-09-16
DE3751845D1 (de) 1996-07-25
EP0446961A3 (en) 1992-04-01
SG50619A1 (en) 1998-07-20
US5093132A (en) 1992-03-03
CA1327010C (fr) 1994-02-15
EP0237200A3 (en) 1988-02-03
EP0446961B1 (fr) 1996-06-19
HK188195A (en) 1995-12-22
EP0423748B1 (fr) 1994-08-24
DE3750431T2 (de) 1994-12-22
EP0237200B1 (fr) 1992-07-01
DE3780045T2 (de) 1992-12-24
DE3750431D1 (de) 1994-09-29
HK1002021A1 (en) 1998-07-24
EP0446961A2 (fr) 1991-09-18
DE3780045D1 (de) 1992-08-06
DE3751845T2 (de) 1996-11-28
EP0423748A1 (fr) 1991-04-24

Similar Documents

Publication Publication Date Title
EP0446961B1 (fr) Composition pharmaceutique stabilisée et sa préparation
US6521256B2 (en) Stabilized pharmaceutical composition
HK1002021B (en) Stabilized pharmaceutical composition and its production
US6749864B2 (en) Stabilized pharmaceutical composition
JPH0338247B2 (fr)
EP0208452B1 (fr) Dérivés de pyridine, leur préparation et utilisation
RU2237666C2 (ru) Калиевая соль (s)-омепразола, способ ее получения и фармацевтический препарат на ее основе
IE904249A1 (en) Therapeutically active chloro substituted benzimidazoles,¹processes for their preparation as well as their use
US7629361B2 (en) Salt of (S)-pantoprazole and its hydrates
JP2762998B2 (ja) 医薬固形組成物用安定化剤および安定化方法
EP0181846B1 (fr) Benzimidazoles substitués, leur préparation et leur utilisation pour l'inhibition de la secrétion des acides gastriques
JPH0825905B2 (ja) 医薬固形組成物用安定化剤および安定化方法
CA1338377C (fr) Composition pharmaceutique stabilisee et sa preparation
KR950007211B1 (ko) 안전화된 약제 조성물 및 항궤양 약제 조성물의 안정화 방법